Suppr超能文献

血浆可溶性 fms 样酪氨酸激酶-1、胎盘生长因子和血管内皮生长因子系统基因变异作为心力衰竭患者生存的预测因子。

Plasma soluble fms-like tyrosine kinase-1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure.

机构信息

Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch, Christchurch, New Zealand.

Cardiology Department, Middlemore Hospital, Auckland, New Zealand.

出版信息

Eur J Heart Fail. 2024 Aug;26(8):1804-1813. doi: 10.1002/ejhf.3368. Epub 2024 Jul 9.

Abstract

AIMS

Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), components of the vascular endothelial growth factor (VEGF) system, play key roles in angiogenesis. Reports of elevated plasma levels of sFlt-1 and PlGF in coronary heart disease and heart failure (HF) led us to investigate their utility, and VEGF system gene single nucleotide polymorphisms (SNPs), as prognostic biomarkers in HF.

METHODS AND RESULTS

ELISA assays for sFlt-1, PlGF and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed on baseline plasma samples from the PEOPLE cohort (n = 890), a study of outcomes among patients after an episode of acute decompensated HF. Eight SNPs potentially associated with sFlt-1 or PlGF levels were genotyped. sFlt-1 and PlGF were assayed in 201 subjects from the Canterbury Healthy Volunteers Study (CHVS) matched to PEOPLE participants. All-cause death was the major endpoint for clinical outcome considered. In PEOPLE participants, mean plasma levels for both sFlt-1 (125 ± 2.01 pg/ml) and PlGF (17.5 ± 0.21 pg/ml) were higher (both p < 0.044) than in the CHVS cohort (81.2 ± 1.31 pg/ml and 15.5 ± 0.32 pg/ml, respectively). sFlt-1 was higher in HF with reduced ejection fraction compared to HF with preserved ejection fraction (p = 0.005). The PGF gene SNP rs2268616 was univariately associated with death (p = 0.016), and was also associated with PlGF levels, as was rs2268614 genotype. Cox proportional hazards modelling (n = 695, 246 deaths) showed plasma sFlt-1, but not PlGF, predicted survival (hazard ratio 6.44, 95% confidence interval 2.57-16.1; p < 0.001) in PEOPLE, independent of age, NT-proBNP, ischaemic aetiology, diabetic status and beta-blocker therapy.

CONCLUSIONS

Plasma sFlt-1 concentrations have potential as an independent predictor of survival and may be complementary to established prognostic biomarkers in HF.

摘要

目的

可溶性 fms 样酪氨酸激酶-1(sFlt-1)和胎盘生长因子(PlGF)是血管内皮生长因子(VEGF)系统的组成部分,在血管生成中发挥关键作用。有报道称,冠心病和心力衰竭(HF)患者的血浆 sFlt-1 和 PlGF 水平升高,这促使我们研究它们作为 HF 预后生物标志物的效用,以及 VEGF 系统基因单核苷酸多态性(SNP)。

方法和结果

对急性失代偿性 HF 发作后患者结局研究(PEOPLE 队列)的基线血浆样本进行 ELISA 检测 sFlt-1、PlGF 和 N 末端 pro-B 型利钠肽(NT-proBNP)。对 8 个可能与 sFlt-1 或 PlGF 水平相关的 SNP 进行基因分型。在与 PEOPLE 参与者相匹配的坎特伯雷健康志愿者研究(CHVS)中,对 201 名参与者进行了 sFlt-1 和 PlGF 检测。全因死亡是考虑的主要临床结局终点。在 PEOPLE 参与者中,sFlt-1(125±2.01 pg/ml)和 PlGF(17.5±0.21 pg/ml)的平均血浆水平均较高(均 p<0.044),而 CHVS 队列中分别为 81.2±1.31 pg/ml 和 15.5±0.32 pg/ml。与射血分数保留的心力衰竭相比,射血分数降低的心力衰竭患者的 sFlt-1 水平更高(p=0.005)。PGF 基因 SNP rs2268616 与死亡单因素相关(p=0.016),与 PlGF 水平相关,rs2268614 基因型也是如此。Cox 比例风险模型(n=695,246 例死亡)显示,在 PEOPLE 中,血浆 sFlt-1 而非 PlGF 可预测生存(危险比 6.44,95%置信区间 2.57-16.1;p<0.001),独立于年龄、NT-proBNP、缺血病因、糖尿病状态和β受体阻滞剂治疗。

结论

血浆 sFlt-1 浓度具有作为生存独立预测因子的潜力,可能是心力衰竭中现有预后生物标志物的补充。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验